On November 18, 2026, the Indian stock market saw significant declines with the Sensex dropping 650 points and the Nifty50 falling below 25,200 during midday trading. This downturn was driven by selling pressure in metal and railway public sector unit (PSU) stocks, along with a weakening rupee and foreign institutional investor outflows.
- The Sensex fell by 650 points, or 0.79%, to 81,882.18.
- The Nifty50 dropped 215.55 points, or 0.85%, to 25,171.85.
- Metal and mining stocks were among the biggest losers.
- IIFL Finance shares rose sharply after a large block deal.
- Biocon gained following European marketing approval for a cancer drug.
- SpiceJet shares hit the upper circuit ahead of a capital raising meeting.
Why did the Sensex and Nifty50 decline on November 18, 2026?
The market decline was mainly due to a sell-off in metal and railway PSU stocks. Global commodity prices fell, and the US dollar strengthened, increasing concerns about a possible interest rate hike by the US Federal Reserve in December. Additionally, the Indian rupee weakened to a record low of 92.37 against the US dollar, influenced by continued foreign institutional investor (FII) outflows for the tenth consecutive day.
Which stocks were the biggest losers and gainers during the session?
Among the Nifty50 stocks, Titan Company, HDFC Life Insurance, Hindalco Industries, Jio Financial Services, and Adani Enterprises were the top losers. On the other hand, Cipla, Tata Consumer Products, Dr. Reddy's Laboratories, Trent, and Oil and Natural Gas Corporation (ONGC) were the leading gainers.
What happened with metal and mining stocks?
Shares of metal and mining companies such as Hindalco Industries, Adani Enterprises, Hindustan Zinc, Steel Authority of India Ltd (SAIL), and Vedanta declined due to falling global commodity prices and the stronger US dollar. The Nifty Metal index dropped as much as 1.83%, marking it as one of the worst-performing sectoral indices on the National Stock Exchange (NSE).
How did IIFL Finance perform and why?
IIFL Finance shares surged by 7.17% to ₹682 after a large block deal was executed involving FIH Mauritius Investments Limited, an investment arm of Canada's Fairfax Financial Holdings. Fairfax put its entire stake in IIFL Finance up for sale, which influenced the stock's sharp rise.
What notable developments occurred with other companies?
Ashoka Buildcon's stock rose 10.1% after winning a ₹1,465 crore order from the National Highways Authority of India (NHAI) for constructing an 8-lane expressway in Gujarat. ACME Solar Holding shares increased by 3.08% following contract wins with a public sector power generation company. Biocon's shares rose 2.35% after receiving European Commission marketing approval for its breast cancer biosimilar drug, Pebrilzo.
What is the significance of Biocon's marketing approval?
The European Commission granted Biocon permission to sell its breast cancer biosimilar drug, Pebrilzo, in the European Union. This approval is important because it allows the company to legally market and distribute the drug in the EU. Biocon's pertuzumab biosimilar is the first to receive marketing authorization under the European Medicines Agency's new clinical approach.
How did SpiceJet's stock perform and why?
SpiceJet's shares were locked at the 5% upper circuit at ₹9.97 ahead of a board meeting to consider raising fresh capital. The company plans to raise funds through equity shares, preference shares, debt securities, or other instruments via preferential issue or qualified institutional placement.
What other corporate actions were noted during the session?
Parag Milk Foods' shares slipped 2% despite allotting 90 lakh equity shares following the conversion of share warrants. The company received ₹161 crore from this conversion. Glenmark Pharmaceuticals' shares rose 2.45% after its subsidiary, Ichnos Glenmark Innovation, submitted an Investigational New Drug (IND) application to the US FDA for a new cancer drug candidate, ISB 2301, which targets solid tumors.
What is the new drug application by Glenmark's subsidiary about?
Ichnos Glenmark Innovation submitted an IND application for ISB 2301, a multispecific immune cell activator designed to target three tumor-associated antigens. It activates both T cells and natural killer cells to fight cancer. The company plans to start Phase 1 clinical trials in 2027.
